Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
Operating Income Growth Recovery in ProgressRecovering
Percentile Rank17
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Percentile
P17
Within normal range
vs 2Y Ago
-8.9x
Contraction
Streak
2 qtr
Consecutive growthRecovering
PeriodValue
Q4 2025-50.77%
Q3 2025-112.00%
Q2 2025-135.32%
Q1 2025238.63%
Q4 2024149.02%
Q3 202418.73%
Q2 20246.60%
Q1 2024-0.24%
Q4 20235.69%
Q3 20230.68%
Q2 2023-8.65%
Q1 2023-5.45%
Q4 2022-14.55%
Q3 2022-4.15%
Q2 2022-12.05%
Q1 2022-3.91%
Q4 2021-17.71%
Q3 2021-9.63%
Q2 2021-57.54%
Q1 20213.62%
Q4 2020-86.91%
Q3 2020-18.35%
Q2 2020-25.69%
Q1 20200.00%